Explore the vast range of titles available.

Monoclonal antibodies (mAbs) have been used in the treatment of various diseases for over 20 years and combine high specificity with generally low toxicity. Their pharmacokinetic properties differ markedly from those of non-antibody-type drugs, and these properties can have important clinical implications. mAbs are administered intravenously, intramuscularly or subcutaneously. Oral administration is precluded by the molecular size, hydrophilicity and gastric degradation of mAbs. Distribution into tissue is slow because of the molecular size of mAbs, and volumes of distribution are generally low. mAbs are metabolized to peptides and amino acids in several tissues, by circulating phagocytic cells or by their target antigen-containing cells. Antibodies and endogenous immunoglobulins are protected from degradation by binding to protective receptors (the neonatal Fc-receptor [FcRn]), which explains their long elimination half-lives (up to 4 weeks). Population pharmacokinetic analyses have been applied in assessing covariates in the disposition of mAbs. Both linear and nonlinear elimination have been reported for mAbs, which is probably caused by target-mediated disposition. Possible factors influencing elimination of mAbs include the amount of the target antigen, immune reactions to the antibody and patient demographics. Bodyweight and/or body surface area are generally related to clearance of mAbs, but clinical relevance is often low. Metabolic drug-drug interactions are rare for mAbs. Exposure-response relationships have been described for some mAbs. In conclusion, the parenteral administration, slow tissue distribution and long elimination half-life are the most pronounced clinical pharmacokinetic characteristics of mAbs.

A growing number of population pharmacokinetic analyses of therapeutic monoclonal antibodies (mAbs) have been published in the scientific literature. The aims of this article are to summarize the findings from these studies and to relate the findings to the general pharmacokinetic and structural characteristics of therapeutic mAbs. A two-compartment model was used in the majority of the population analyses to describe the disposition of the mAb. Population estimates of the volumes of distribution in the central (V 1 ) and peripheral (V 2 ) compartments were typically small, with median (range) values of 3.1 (2.4–5.5) L and 2.8 (1.3–6.8) L, respectively. The estimated between-subject variability in the V 1 was usually moderate, with a median (range) coefficient of variation (CV) of 26% (12–84%). Between-subject variability in other distribution-related parameters such as the V 2 and intercompartmental clearance were often not estimated. Although the pharmacokinetic models used most frequently in the population analyses were models with linear clearance, other models with nonlinear, or parallel linear and nonlinear clearance pathways were also applied, as many therapeutic mAbs are eliminated via saturable target-mediated mechanisms. Population estimates of the maximum elimination rate (V max ) and the mAb concentration at which elimination was at half maximum for Michaelis-Menten-type elimination pathways varied considerably among the different therapeutic mAbs. However, estimates of the total clearance (CL) of mAbs with linear clearance characteristics and of the clearance of mAbs via the linear clearance pathway (CL L ) with parallel linear and nonlinear clearance were quite similar for the different mAbs and typically ranged from 0.2 to 0.5 L/day, which is relatively close to the estimated clearance of endogenous IgG of 0.21 L/day. The between-subject variability in the V max , CL and CL L was moderate to high, with estimated CVs ranging from 15% to 65%. Measures of body size were the covariates most commonly identified as influencing the pharmacokinetics of therapeutic mAbs. In summary, many features of the population pharmacokinetics of currently used therapeutic mAbs are similar, despite differences in their pharmacological targets and studied patient populations.

The unique features of millimeter waves (mmWaves) motivate its leveraging to future, beyond-fifth-generation/sixth-generation (B5G/6G)-based device-to-device (D2D) communications. However, the neighborhood discovery and selection (NDS) problem still needs intelligent solutions due to the trade-off of investigating adjacent devices for the optimum device choice against the crucial beamform training (BT) overhead. In this paper, by making use of multiband (μW/mmWave) standard devices, the mmWave NDS problem is addressed using machine-learning-based contextual multi-armed bandit (CMAB) algorithms. This is done by leveraging the context information of Wi-Fi signal characteristics, i.e., received signal strength (RSS), mean, and variance, to further improve the NDS method. In this setup, the transmitting device acts as the player, the arms are the candidate mmWave D2D links between that device and its neighbors, while the reward is the average throughput. We examine the NDS’s primary trade-off and the impacts of the contextual information on the total performance. Furthermore, modified energy-aware linear upper confidence bound (EA-LinUCB) and contextual Thomson sampling (EA-CTS) algorithms are proposed to handle the problem through reflecting the nearby devices’ withstanding battery levels, which simulate real scenarios. Simulation results ensure the superior efficiency of the proposed algorithms over the single band (mmWave) energy-aware noncontextual MAB algorithms (EA-UCB and EA-TS) and traditional schemes regarding energy efficiency and average throughput with a reasonable convergence rate.

Several mAbs have been tested or are currently under clinical evaluation for the treatment of COPD. They can be subdivided into those that aim to block specific pro-inflammatory and pro-neutrophilic cytokines and chemokines, such as TNF-[alpha], IL-1[beta], CXCL8 and IL-1[beta], and those that act on T2-mediated inflammation, respectively, by blocking IL-5 and/or its receptor, preventing IL-4 and IL-13 signaling, affecting IL-33 pathway and blocking TSLP. None of these approaches has proved to be effective, probably because in COPD there is no dominant cytokine or chemokine and, therefore, a single mAb cannot be effective on all pathways. With a more in-depth understanding of the numerous pheno/ endotypic pathways that play a role in COPD, it may eventually be possible to identify those specific patients in whom some of these cytokines or chemokines might predominate. In this case, it will be possible to implement a personalized treatment, but the use of each mAb will only be reserved for a very limited number of subjects. Keywords: COPD, monoclonal antibodies, pheno/endotypic pathways, anti-T1-mediated inflammation mAbs, anti-T2-mediated inflammation mAbs

Host cell proteins (HCPs) are process-related impurities that are generated by the host organism, and are typically present at low levels in therapeutic monoclonal antibody (mAb) and other recombinant biopharmaceutical products. Firstly, a high-pH–low-pH “two-dimensional” reversed-phase nano-LC–MS/MS label-free quantification (2D nano-LC–MS/MS LFQ) method with a robust stability (CV% < 20%) was developed. Subsequently, this study developed economical hexamer ligand (HWRGWV) magnetic beads (HLMB), which aim to improve the sensitivity and reliability of HCP detection and has an IgG antibody-binding capacity similar to that of Protein A. In turn, the HCP study based on 2D nano-LC–MS/MS, a comparison between the removal and the reservation of the main antibody components was developed, and the qualitative and quantitative results were compared among HLMB/Protein A depletion and other two pretreatment processes. Results of this study indicated that after using HLMB/ProA material for antibody primary component removal, the content of HCPs in the elution buffer (associated or co-purified with the antibody) was significantly higher than that in the flow-through. In total, 22 kinds of HCPs were co-identified in HLMB eluent and ProA eluent, in which most of the HCPs exhibited weak alkalinity, while the sensitivity of HCPs identified with a low molecular weight (ranging from 13 to 21 kDa) was as low as 0.1 ppm. Together, this study established an economical and effective approach to comprehensively evaluate HCPs in antibodies, while also globally presenting the impact of major antibody components on the qualitative and quantitative analyses of HCPs. Graphical Abstract

Hexagonal MAB phases （h‐MAB） have attracted attention due to their potential to exfoliate into MBenes, similar to MXenes, which are predicted to be promising for Li‐ion battery applications. However, the high cost of synthesizing MBenes poses challenges for their use in batteries. This study presents a novel approach where a simple ball‐milling treatment is employed to enhance the purity of the h‐MAB phase Ti2InB2 and introduce significant indium defects, resulting in improved conductivity and the creation of abundant active sites. The synthesized Ti2InB2 with indium defects (VIn‐Ti2InB2) exhibits excellent electrochemical properties, particularly exceptional long‐cycle stability at current densities of 5 A g−1 (5000 cycles, average capacity decay of 0.0018%) and 10 A g−1 (15 000 cycles, average capacity decay of 0.093%). The charge storage mechanism of VIn‐Ti2InB2, involving a dual redox reaction, is proposed, where defects promote the In‐Li alloy reaction and a redox reaction with Li in the TiB layer. Finally, a Li‐ion full cell demonstrates cycling stability at 0.5 A g−1 after 350 cycles. This work presents the first accessible and scalable application of VIn‐Ti2InB2 as a Li‐ion anode, unlocking a wealth of possibilities for sustainable electrochemical applications of h‐MAB phases. This work presents a simple and effective approach to introducing indium defects into the h‐MAB phase Ti2InB2, which exhibits exceptional long‐term cycling stability. This study highlights the novel functionality of h‐MAB phases in lithium‐ion batteries, shedding light on their potential applications in energy storage and beyond.

Monoclonal antibodies (mAbs) are used to prevent, detect, and treat a broad spectrum of non-communicable and communicable diseases. Over the past few years, the market for mAbs has grown exponentially with an expected compound annual growth rate (CAGR) of 11.07% from 2024 (237.64 billion USD estimated at the end of 2023) to 2033 (679.03 billion USD expected by the end of 2033). Ever since the advent of hybridoma technology introduced in 1975, antibody-based therapeutics were realized using murine antibodies which further progressed into humanized and fully human antibodies, reducing the risk of immunogenicity. Some benefits of using mAbs over conventional drugs include a drastic reduction in the chances of adverse reactions, interactions between drugs, and targeting specific proteins. While antibodies are very efficient, their higher production costs impede the process of commercialization. However, their cost factor has been improved by developing biosimilar antibodies as affordable versions of therapeutic antibodies. Along with the recent advancements and innovations in antibody engineering have helped and will furtherly help to design bio-better antibodies with improved efficacy than the conventional ones. These novel mAb-based therapeutics are set to revolutionize existing drug therapies targeting a wide spectrum of diseases, thereby meeting several unmet medical needs. This review provides comprehensive insights into the current fundamental landscape of mAbs development and applications and the key factors influencing the future projections, advancement, and incorporation of such promising immunotherapeutic candidates as a confrontation approach against a wide list of diseases, with a rationalistic mentioning of any limitations facing this field.

Antibodies (mAbs) are attractive molecules for their application as a diagnostic and therapeutic agent for diseases of the central nervous system (CNS). mAbs can be generated to have high affinity and specificity to target molecules in the CNS. Unfortunately, only a very small number of mAbs have been specifically developed and approved for neurological indications. This is primarily attributed to their low exposure within the CNS, hindering their ability to reach and effectively engage their potential targets in the brain. This review discusses aspects of various barriers such as the blood–brain barrier (BBB) and blood–cerebrospinal fluid (CSF) barrier (BCSFB) that regulate the entry and clearance of mAbs into and from the brain. The roles of the glymphatic system on brain exposure and clearance are being described. We also discuss the proposed mechanisms of the uptake of mAbs into the brain and for clearance. Finally, several methods of enhancing the exposure of mAbs in the CNS were discussed, including receptor-mediated transcytosis, osmotic BBB opening, focused ultrasound (FUS), BBB-modulating peptides, and enhancement of mAb brain retention.

INTRODUCTION In EMERGE (NCT02484547), participants receiving aducanumab had significantly less progression versus placebo on all prespecified clinical endpoints at week 78. Here, we explicate the clinical meaningfulness of these treatment effects by analyzing item‐level data and the persistence of treatment benefit. METHODS Participants with early Alzheimer's disease (AD) were stratified by apolipoprotein E (APOE) ε4 status and randomized (1:1:1) to receive low‐ or high‐dose aducanumab, or placebo. Prespecified principal component analyses (PCAs) per the Statistical Analysis Plan were followed by post hoc examination of individual domains/items across all five clinical endpoints. Progression analysis assessed reduction in clinical decline. RESULTS High‐dose aducanumab demonstrated clinically meaningful slowing of progression across clinical endpoints measuring cognition, daily function, and behavioral symptoms. Delay of progression over 18 months was consistent across measures; treatment effects increased over time. DISCUSSION Across multiple analyses aducanumab slowed cognitive decline, prolonged functional independence, and attenuated behavioral symptoms in participants with early AD. These outcomes comprise the elements of a clinically meaningful response to treatment. Highlights Endpoints in EMERGE assessed different aspects of cognition, daily function, and behavioral symptoms. Treatment benefits were observed across subdomains on all five clinical endpoints. Aducanumab meaningfully slowed disease progression in participants with early AD.